Imatinib: The controversial discussion on cardiotoxicity induced by endoplasmic reticulum (ER) stress

Archives of Toxicology

Volumn 86, Issue 3, 2012, Pages 339-340

  Marchan, R ^a   Bolt, H M ^a  

^a TU DORTMUND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; STRESS ACTIVATED PROTEIN KINASE; TRASTUZUMAB;

CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; DRUG TOLERABILITY; EDITORIAL; ENDOPLASMIC RETICULUM STRESS; GASTROINTESTINAL STROMAL TUMOR; HEART FAILURE; HEART MUSCLE CELL; HUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION;

ANTINEOPLASTIC AGENTS; ENDOPLASMIC RETICULUM STRESS; HEART; HUMANS; PIPERAZINES; PYRIMIDINES;

EID: 84858074123     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-012-0813-7     Document Type: Editorial

References (18)

1. Brase JC, Schmidt M, Fischbach T, Sültmann H, Bojar H, Koelbl H, Hellwig B, Rahnenführer J, Hengstler JG, Gehrmann MC (2010) ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin Cancer Res 16(8):2391-2401
2. Cadenas C, Franckenstein D, Schmidt M, Gehrmann M, Hermes M, Geppert B, Schormann W, Maccoux LJ, Schug M, Schumann A, Wilhelm C, Freis E, Ickstadt K, Rahnenführer J, Baumbach JI, Sickmann A, Hengstler JG (2010) Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer. Breast Cancer Res 12(3):R44
3. Hellwig B, Hengstler JG, Schmidt M, Gehrmann MC, Schormann W, Rahnenführer J (2010) Comparison of scores for bimodality of gene expression distributions and genome-wide evaluation of the prognostic relevance of high-scoring genes. BMC Bioinf 25(11):276
4. Herman EH, Knapton A, Rosen E, Thompson K, Rosenzweig B, Estis J, Agee S, Lu QA, Todd JA, Lipshultz S, Hasinoff B, Zhang J (2011) A multifaceted evaluation of imatinib-induced cardiotoxicity in the rat. Toxicol Pathol 39(7):1091-1106
5. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344(14):1052-1056 (Pubitemid 32267975)
6. Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ, Rosenzweig A, Salomon RN, Van Etten RA, Alroy J, Durand JB, Force T (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12(8):908-916 (Pubitemid 44175142)
7. Lee JH, Jung C, Javadian-Elyaderani P, Schweyer S, Schütte D, Shoukier M, Karimi-Busheri F, Weinfeld M, Rasouli-Nia A, Hengstler JG, Mantilla A, Soleimanpour-Lichaei HR, Engel W, Robson CN, Nayernia K (2010) Pathways of proliferation and antiapoptosis driven in breast cancer stem cells by stem cell protein piwil2. Cancer Res 70(11):4569-4579
8. Micke P, Basrai M, Faldum A, Bittinger F, Rönnstrand L, Blaukat A, Beeh KM, Oesch F, Fischer B, Buhl R, Hengstler JG (2003) Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin Cancer Res 9(1):188-194 (Pubitemid 36109732)
9. Micke P, Hengstler JG, Albrecht H, Faldum A, Bittinger F, Becker K, Wiewrodt R, Fischer B, Buhl R (2004) Characterization of c-kit expression in adenocarcinomas of the lung. Tumour Biol 25(5-6):235-242
10. Petry IB, Fieber E, Schmidt M, Gehrmann M, Gebhard S, Hermes M, Schormann W, Selinski S, Freis E, Schwender H, Brulport M, Ickstadt K, Rahnenführer J, Maccoux L, West J, Kölbl H, Schuler M, Hengstler JG (2010) ERBB2 induces an antiapoptotic expression pattern of Bcl-2 family members in node-negative breast cancer. Clin Cancer Res 16(2):451-460
11. Ribeiro AL, Marcolino MS, Bittencourt HN, Barbosa MM, Nunes Mdo C, Xavier VF, Clementino NC (2008) An evaluation of the cardiotoxicity of imatinib mesylate. Leuk Res 32(12):1809-1814
12. Schmidt M, Böhm D, von Törne C, Steiner E, Puhl A, Pilch H, Lehr HA, Hengstler JG, Kölbl H, Gehrmann M (2008) The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68(13):5405-5413
13. Schmidt M, Petry IB, Böhm D, Lebrecht A, von Törne C, Gebhard S, Gerhold-Ay A, Cotarelo C, Battista M, Schormann W, Freis E, Selinski S, Ickstadt K, Rahnenführer J, Sebastian M, Schuler M, Koelbl H, Gehrmann M, Hengstler JG (2010) Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer. Breast Cancer Res Treat 125(3):637-646
14. Sumi D, Sasaki T, Miyataka H, Himeno S (2011) Rat H9c2 cardiac myocytes are sensitive to arsenite due to a modest activation of transcription factor Nrf2. Arch Toxicol 85(12):1509-1516
15. Thanopoulou E, Judson I (2012) The safety profile of imatinib in CML and GIST: long-term considerations. Arch Toxicol 86:1-12
16. Van Etten RA (2004) Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. Leuk Res 28:21-28
17. Vávrová A, Popelová O, Stěrba M, Jirkovský E, Hašková P, Mertlíková- Kaiserová H, Geršl V, Simu° nek T (2011) In vivo and in vitro assessment of the role of glutathione antioxidant system in anthracycline- induced cardiotoxicity. Arch Toxicol 85(5):525-535
18. Wolf A, Couttet P, Dong M, Grenet O, Heron M, Junker U, Laengle U, Ledieu D, Marrer E, Nussher A, Persohn E, Pognan F, Rivière GJ, Roth DR, Trendelenburg C, Tsao J, Roman D (2010) Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies. Leuk Res 34(9):1180-1188